Cargando…

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies (HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, including those ineligible for peginterferon (H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sarrazin, Christoph, Castelli, Francesco, Andreone, Pietro, Buti, Maria, Colombo, Massimo, Pol, Stanislas, Calinas, Filipe, Puoti, Massimo, Olveira, Antonio, Shiffman, Mitchell, Stern, Jerry O, Kukolj, George, Roehrle, Michael, Aslanyan, Stella, Deng, Qiqi, Vinisko, Richard, Mensa, Federico J, Nelson, David R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125810/ https://www.ncbi.nlm.nih.gov/pubmed/27920566 http://dx.doi.org/10.2147/CEG.S111116

Ejemplares similares

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment
por: Sarrazin, Christoph, et al.
Publicado: (2016)

Resistance Analyses of HCV NS3/4A Protease and NS5B Polymerase from Clinical Studies of Deleobuvir and Faldaprevir
por: Berger, Kristi L., et al.
Publicado: (2016)

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection
por: Asselah, Tarik, et al.
Publicado: (2015)

Faldaprevir for the Treatment of Hepatitis C
por: Kanda, Tatsuo, et al.
Publicado: (2015)

SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
por: Dieterich, Douglas, et al.
Publicado: (2014)

Circulating sCD14 Is Associated with Virological Response to Pegylated-Interferon-Alpha/Ribavirin Treatment in HIV/HCV Co-Infected Patients
por: Marchetti, Giulia, et al.
Publicado: (2012)

Ribavirin
Publicado: (2016)

Ribavirin
por: Hall, Caroline Breese
Publicado: (1985)

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
por: Forns, Xavier, et al.
Publicado: (2015)

Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies
por: Tavitian, Suzanne, et al.
Publicado: (2015)

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
por: Asselah, Tarik, et al.
Publicado: (2016)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
por: Pol, Stanislas, et al.
Publicado: (2016)

Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin
por: Feld, Jordan J., et al.
Publicado: (2018)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
por: Flamm, Steven, et al.
Publicado: (2023)

Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients
por: Taramasso, Lucia, et al.
Publicado: (2018)

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
por: Shiffman, Mitchell L, et al.
Publicado: (2016)

RIBAVIRIN AND RESPIRATORY SYNCYTIAL VIRUS
Publicado: (1986)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017)

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin
por: Asselah, Tarik, et al.
Publicado: (2016)

Comparative study between Ribavirin and Ribavirin plus Intravenous Immunoglobulin against Crimean Congo hemorrhagic fever
por: Salehi, Hassan, et al.
Publicado: (2013)

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
por: Grebely, Jason, et al.
Publicado: (2018)

Hepatology in the COVID Era: Another C Virus, again Challenging the Liver
por: Peixe, Paula, et al.
Publicado: (2020)

Ribavirin for Lassa Fever Postexposure Prophylaxis
por: Hadi, Christiane M., et al.
Publicado: (2010)

Kinetic Determination of Ribavirin in Drug Formulations
por: El-Brashy, A. M., et al.
Publicado: (2007)

Bioproduction of ribavirin by green microbial biotransformation
por: Rivero, Cintia W., et al.
Publicado: (2015)

Early Treatment with Ribavirin may be Considered
Publicado: (2013)

Ribavirin: Bradycardia: 3 case reports
Publicado: (2016)

1356. Ribavirin Use in Hospitalized Children
por: Otto, William R, et al.
Publicado: (2020)

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
por: Asselah, Tarik, et al.
Publicado: (2017)

High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
por: Pellicelli, Adriano, et al.
Publicado: (2020)

PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C
por: Markova, Antoaneta A., et al.
Publicado: (2014)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Selection of hepatitis C virus resistant to ribavirin
por: Feigelstock, Dino A, et al.
Publicado: (2011)

Ribavirin for treating Crimean Congo haemorrhagic fever
por: Johnson, Samuel, et al.
Publicado: (2018)

Screening therapeutic targets of ribavirin in hepatocellular carcinoma
por: Xu, Chen, et al.
Publicado: (2018)

Ribavirin efficiently suppresses porcine nidovirus replication
por: Kim, Youngnam, et al.
Publicado: (2013)

Ribavirine : au revoir VHC, bonjour VHE
Publicado: (2014)

Ribavirin: Thrombocytopenia and decrease in haemoglobin: case report
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7b9ormucq5u78q894435a9cqdr